Kamada and Baxter enter into a strategic agreement for the distribution and manufacture of Intravenous Liquid AAT to treat Alpha-1 Antitrypsin Deficiency in the US August 24, 2010
Kamada will receive up to US$ 45 million of milestone payments of which...
